Combination 5-azacytidine and nivolumab

Phase 2Monoclonal antibody

Combination 5-azacytidine and nivolumab is one of 6 small molecule programs targeting Azacytidine. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AzacytidineRecruiting

AzacytidinePhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Azacytidine

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Istodax

Teva

Phase 2

1 3

Opdualag

Bristol-Myers Squibb

Phase 2

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 5

Azacytidine

AArog Pharmaceuticals, Inc.

Phase 2

2 6

Combination 5-azacytidine and nivolumab

BBarbara Burtness

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Azacytidine

NCT05317000

Clinical

Trials by Indication[1]

Azacytidine1 trial

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Recruiting·BBarbara Burtness·Phase 2·NCT05317000·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combination 5-azacytidine and nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination 5-azacytidine and nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination 5-azacytidine and nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Barbara Burtness company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: BBarbara Burtness

Combination 5-azacytidine and nivolumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Azacytidine1 trial

References

Drug Info

Quick Facts

Related News